|
Myeloid Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias.
|
15187020 |
2004 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
|
16878152 |
2007 |
|
Cardiomyopathy, Dilated
|
0.010 |
AlteredExpression
|
group |
BEFREE |
NMU-25 precursor mRNA was upregulated in the left ventricle from patients with dilated cardiomyopathy and ischaemic heart disease.
|
18987052 |
2009 |
|
Coronary Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NMU-25 precursor mRNA was upregulated in the left ventricle from patients with dilated cardiomyopathy and ischaemic heart disease.
|
18987052 |
2009 |
|
Myocardial Ischemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NMU-25 precursor mRNA was upregulated in the left ventricle from patients with dilated cardiomyopathy and ischaemic heart disease.
|
18987052 |
2009 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.
|
19118941 |
2009 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.
|
19118941 |
2009 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
NMU (Neuromedin U) is a neuropeptide that has been implicated in energy homeostasis and tumour progression.
|
21791076 |
2011 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Neuromedin U (NMU) activates two G protein-coupled receptors, NMUR1 and NMUR2; this signaling not only controls many physiological responses but also promotes tumorigenesis in diverse tissues.
|
26317338 |
2015 |
|
Pituitary Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Neuromedin U (NMU) is a neuropeptide known to regulate food intake and energy homeostasis that is widely distributed in the gastrointestinal tract, hypothalamus, and pituitary.
|
28291683 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Neuromedin U (NMU) has been shown driving the progression of various tumor entities, including breast cancer.
|
28423716 |
2017 |
|
Anorexia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects.
|
29057457 |
2018 |
|
HER2-positive carcinoma of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Neuromedin U (NmU) -a neuropeptide belonging to the neuromedin family- plays a substantial role in HER2-positive breast cancer, correlating with increased aggressiveness, resistance to HER2-targeted therapies and overall significantly poorer outcome for patients.
|
29209569 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Neuromedin U: A Small Peptide in the Big World of Cancer.
|
31492042 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Neuromedin U: A Small Peptide in the Big World of Cancer.
|
31492042 |
2019 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Neuromedin U (NMU), a neuropeptide isolated from porcine spinal cord and named because of its activity as a rat uterus smooth muscle contraction inducer, is emerging as a new player in the tumorigenesis and/or metastasis of many types of cancers.
|
31492042 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Neuromedin U (NMU), a neuropeptide isolated from porcine spinal cord and named because of its activity as a rat uterus smooth muscle contraction inducer, is emerging as a new player in the tumorigenesis and/or metastasis of many types of cancers.
|
31492042 |
2019 |
|
Obesity
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
A total of 289 Czech children and adolescents with early-onset obesity and 84 Danish obese adults were analyzed for variants in NMU.
|
16984985 |
2006 |
|
Obesity
|
0.250 |
Biomarker
|
disease |
RGD |
After 1 month of the high-fat diet, however, the obesity-resistant rats showed significantly more NMU-induced physical activity compared to the obese DIO rats.
|
17706946 |
2007 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Although NMU overexpression did not increase the monolayer growth of T24 or related T24T poorly metastatic human bladder cancer cells, it did augment anchorage-independent growth for the latter.
|
16878152 |
2007 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Although NmU exerted no effects on cancer cell proliferation, it induced c-Met and a trend towards increased invasiveness as well as an increased hepatocyte growth factor (HGF)-mediated scattering.
|
19118941 |
2009 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Although NmU exerted no effects on cancer cell proliferation, it induced c-Met and a trend towards increased invasiveness as well as an increased hepatocyte growth factor (HGF)-mediated scattering.
|
19118941 |
2009 |
|
Overweight and obesity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Amino acid variants in NMU associate with overweight and obesity, suggesting that NMU is involved in energy regulation in humans.
|
16984985 |
2006 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
An analysis of 3,489 cases of breast cancer showed NmU to be associated with poor patient outcome, particularly those with HER2-overexpressing tumors independent of established prognostic indicators.
|
24876102 |
2014 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
An analysis of 3,489 cases of breast cancer showed NmU to be associated with poor patient outcome, particularly those with HER2-overexpressing tumors independent of established prognostic indicators.
|
24876102 |
2014 |